Hospital Universitari Vall d'Hebron

Barcelona, Catalonia 119-129

14 studies enrolling now · 56 studies all time

What they study most

Active Refractory Rheumatoid Arthritis, Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, Advanced Non CNS Tumors, Advanced Solid Tumor, Advanced Solid Tumors, Aortic Aneurysm, Aortic Diseases, Aortic Dissection, Asthma, Atherosclerotic Cardiovascular Disease, B Cell Precursor Acute Lymphoblastic Leukemia, COVID

Studies at this site

• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — Recruiting now
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) — Recruiting now
• AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors — Recruiting now
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) — Recruiting now
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy — Recruiting now
• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors — Recruiting now
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation — Recruiting now
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) — Recruiting now
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) — Recruiting now
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy — Recruiting now
• Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease — Recruiting now
• Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation — Completed
• A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) — Running, not enrolling
• Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. — Running, not enrolling
• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. — Stopped early
• Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine — Running, not enrolling
• Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia — Running, not enrolling
• A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression — Stopped early
• Registry of Asthma Patients Initiating DUPIXENT® — Completed
• A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) — Running, not enrolling
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors — Running, not enrolling
• Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). — Running, not enrolling
• A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL — Running, not enrolling
• Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta — Running, not enrolling
• Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) — Running, not enrolling
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) — Running, not enrolling
• PM14 Administered Intravenously to Patients With Advanced Solid Tumors — Completed
• Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) — Running, not enrolling
• A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors — Completed
• Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery — Running, not enrolling
• Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine — Completed
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Running, not enrolling
• First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) — Running, not enrolling
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — Running, not enrolling
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
• Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors — Completed
• Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma — Running, not enrolling
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — Running, not enrolling
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling
• Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) — Running, not enrolling
• A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) — Running, not enrolling
• Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers — Stopped early
• Study of AMG 256 in Adult Subjects With Advanced Solid Tumors — Completed
• A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache — Completed
• AMG 404 in Patients With Advanced Solid Tumors — Completed
• A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) — Stopped early